참고문헌
- Andre T, Louvet C, Maindrault-Goebel F, et al (1999). CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer, 35, 1343-7. https://doi.org/10.1016/S0959-8049(99)00150-1
- Bajetta E, Di Bartolomeo M, Mariani L, et al (2004). Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. Cancer, 100, 279-87. https://doi.org/10.1002/cncr.11910
- Bajsa J, Pan Z, Duke SO (2011). Transcriptional responses to cantharidin, a protein phosphatase inhibitor, in Arabidopsis thaliana reveal the involvement of multiple signal transduction pathways. Physiol Plant, 143, 188-205. https://doi.org/10.1111/j.1399-3054.2011.01494.x
- Borner MM, Bernhard J, Dietrich D, et al (2005). A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity. Ann Oncol, 16, 282-8. https://doi.org/10.1093/annonc/mdi047
- Cartwright T, Lopez T, Vukelja SJ, et al (2005). Results of a phase II open-label study of capecitabine in combination with irinotecan as first-line treatment for metastatic colorectal cancer. Clin Colorectal Cancer, 5, 50-6. https://doi.org/10.3816/CCC.2005.n.016
- Chen HJ, Wu AG (2004). A clinical study on cantharidin combined with 5-Fu/CF in treating patients with advanced colorectal cancer. J Chinese Doctor.
- De Gramont A, Figer A, Seymour M, et al (2000). Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol, 18, 2938-47.
- De Gramont A, Kindler HL (2002). Pemetrexed in patients with gastrointestinal carcinoma. Semin Oncol, 29, 42-9. https://doi.org/10.1053/sonc.2002.30763
- Douillard JY, Cunningham D, Roth AD, et al (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 355, 1041-7. https://doi.org/10.1016/S0140-6736(00)02034-1
- Douillard JY, Cunningham D, Roth AD, et al (2000). Irinotecan combined with fluorouracil compared with fluorouracil alone. As first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet, 25, 1041-7.
- Fan LJ (2009). A clinical observation on Cantharidin B6 5-Fu and CF in treating patients with advanced colorectal cancer. Mod Med J China, 11, 64-5
- Fan QL, Wang Y (2013). A clinical study on Cantharidin B6 and S-1 in treating patients with advanced gastrointestinal cancer. Guang Ming Chin Med, 28, 4.
- Fuchs CS, Marshall J, Mitchell E, et al (2007). Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study. J Clin Oncol, 25, 4779-86. https://doi.org/10.1200/JCO.2007.11.3357
- Garcia-Alfonso P, Munoz-Martin A, Mendez-Urena M, et al (2009). Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group. Br J Cancer, 101, 1039-43. https://doi.org/10.1038/sj.bjc.6605261
- He F, Fan T (2014). Cantharidin and mFOLFOX6 in treating patients with colorectal cancer. J Med Sci Central South China, 3, 311-3
- Hsieh CH, Huang YC, Tsai TH, et al (2011). Cantharidin modulates development of human monocyte-derived dendritic cells. Toxicol In Vitro, 25, 1740-7. https://doi.org/10.1016/j.tiv.2011.09.001
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90 https://doi.org/10.3322/caac.20107
- Kohne CH, De Greve J, Hartmann JT, et al (2008). Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015. Ann Oncol, 19, 920-6. https://doi.org/10.1093/annonc/mdm544
- Kohne CH, Van Cutsem E, Wils J, et al (2005). Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. J Clin Oncol, 23, 4856-65. https://doi.org/10.1200/JCO.2005.05.546
- Liu D, Chen Z (2009). The effects of cantharidin and cantharidin derivates on tumour cells. Anticancer Agents Med Chem, 9, 392-6. https://doi.org/10.2174/1871520610909040392
- Miwa M, Ura M, Nishida M, et al (1998). Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer, 34, 1274-81. https://doi.org/10.1016/S0959-8049(98)00058-6
- Parkin DM, Bray F, Ferlay J, Pisani P (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108. https://doi.org/10.3322/canjclin.55.2.74
- Patt YZ, Lee FC, Liebmann JE, et al (2007). Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results. Am J Clin Oncol, 30, 350-7. https://doi.org/10.1097/COC.0b013e31804b40bb
- Saltz LB, Cox JV, Blanke C, et al (2000). Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. New Engl J Med, 343, 905-14. https://doi.org/10.1056/NEJM200009283431302
- Shanghai municipal center for disease control and prevention: Shanghai Cancer Report 2007.
- Van Cutsem E, Findlay M, Osterwalder B, et al (2000). Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol, 18, 1337-45.
- Van Cutsem E, Nordlinger B, Adam R, et al (2006). Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur J Cancer, 42, 2212-21. https://doi.org/10.1016/j.ejca.2006.04.012
- Verma AK, Prasad SB (2012). Bioactive component, cantharidin from Mylabris cichorii and its antitumor activity against Ehrlich ascites carcinoma. Cell Biol Toxicol, 28, 133-47. https://doi.org/10.1007/s10565-011-9206-6
- Wang L, Huang XE, Cao J (2014). Clinical study on safety of cantharidin sodium and shenmai injection combined with chemotherapy in treating patients with breast cancer postoperatively. Asian Pac J Cancer Prev, 15, 5597-600 https://doi.org/10.7314/APJCP.2014.15.14.5597
- Xu Y, Zhao AG, Li ZY (2012). Survival benefit of traditional chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer. Integr Cancer Ther, 9, 9.
- Yoo PS, Lopez-Soler RI, Longo WE, et al (2006). Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clin Colorectal Cancer, 6, 202-7. https://doi.org/10.3816/CCC.2006.n.036
-
Zhan YP, Huang XE, Cao J (2012). Clinical study on safety and efficacy of
$Qinin^{(R)}$ (cantharidin sodium) injection combined with chemotherapy in treating patients with gastric cancer. Asian Pacific J Cancer Prev, 13, 4773-6 https://doi.org/10.7314/APJCP.2012.13.9.4773
피인용 문헌
- The advantages of using traditional Chinese medicine as an adjunctive therapy in the whole course of cancer treatment instead of only terminal stage of cancer vol.9, pp.1, 2015, https://doi.org/10.5582/bst.2015.01019